Status:
NO_LONGER_AVAILABLE
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Lead Sponsor:
Eisai Inc.
Conditions:
Cancer
Eligibility:
All Genders
Brief Summary
The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is r...
Detailed Description
The Access Program will be provided as long as appropriate according to the judgment of the provider. If Denileukin diftitox (ONTAK) becomes commercially available without restriction, then the access...
Eligibility Criteria
Inclusion
- To receive denileukin diftitox (ONTAK) under this protocol, the patient's physician must request this therapy for the specific patient. Patients may continue treatment with denileukin diftitox if they:
- Are currently on therapy with denileukin diftitox and require ongoing therapy to maintain control of their disease.
- Are willing and able to comply with all aspects of the Access Protocol
- Provide written informed consent to participate
Exclusion
- Patients are not eligible for the Access Program with denileukin diftitox if they:
- • Are not currently on denileukin diftitox therapy
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01432483
Last Update
January 26 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.